🇺🇸 Hydroxychloroquine Sulfate Tablets in United States

243 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Product Use In Unapproved Indication — 35 reports (14.4%)
  2. Drug Ineffective — 33 reports (13.58%)
  3. Off Label Use — 33 reports (13.58%)
  4. Pruritus — 24 reports (9.88%)
  5. Rash — 23 reports (9.47%)
  6. Joint Swelling — 21 reports (8.64%)
  7. Peripheral Swelling — 20 reports (8.23%)
  8. Arthralgia — 18 reports (7.41%)
  9. Dyspnoea — 18 reports (7.41%)
  10. Electrocardiogram Qt Prolonged — 18 reports (7.41%)

Source database →

Hydroxychloroquine Sulfate Tablets in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Hydroxychloroquine Sulfate Tablets approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Hydroxychloroquine Sulfate Tablets in United States?

Xingchen Peng is the originator. The local marketing authorisation holder may differ — check the official source linked above.